European Commission Authorizes Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026–2027 Season
核心洞察
The European Commission granted marketing authorization for Pfizer and BioNTech's updated COVID-19 (搜索) vaccine targeting the XFG variant of the JN.1 lineage for individuals aged 6 months and older.
The authorization follows the EMA's Emergency Task Force recommendation that targeting XFG would provide the best protection against currently circulating SARS-CoV-2 strains.
Non-clinical data demonstrated strong immune responses against XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other contemporary lineages.
Pfizer Inc. and BioNTech SE announced on July 29, 2026, that the European Commission (EC) has granted marketing authorization for their 2026–2027 COVID-19 (搜索) vaccine formula, which targets the XFG variant of the JN.1 lineage. The vaccine is authorized for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older, and the authorization is valid across all 27 European Union Member States as well as Iceland, Liechtenstein, and Norway.
The adaptation follows a recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA), which stated that "the evidence suggests that targeting XFG would provide the best protection against COVID-19 (搜索)." The ETF's guidance shaped the strain selection for the upcoming respiratory disease season, when demand for COVID-19 vaccination is expected to rise.
Regulatory Pathway and Supporting Evidence
The EC approval builds on the EMA's Committee for Medicinal Products for Human Use (CHMP) recommendation issued on July 23, 2026. The CHMP based its positive opinion on a cumulative body of evidence previously submitted by Pfizer and BioNTech, encompassing clinical, non-clinical, and real-world data supporting the safety and efficacy of the companies' COVID-19 (搜索) vaccine platform.
Specifically, manufacturing and quality data, along with non-clinical immunogenicity data, showed that the monovalent XFG-adapted COVID-19 vaccine (搜索) generated strong immune responses against currently circulating SARS-CoV-2 lineages. These include XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other contemporary lineages.
Manufacturing and Supply Readiness
Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine (搜索) at risk, a strategic move designed to ensure supply readiness in anticipation of the respiratory disease season. EU Member States, as well as Norway, will be supplied either via the EC contract or according to individual country government policies. Shipping is expected to begin soon to facilitate rapid access to the updated vaccine.
Global Regulatory Submissions and Ongoing Surveillance
The companies have submitted data for the updated COVID-19 (搜索) vaccine to regulatory authorities around the world and continue to monitor the evolving epidemiology of COVID-19 to meet global public health needs. To date, more than five billion doses of the Pfizer-BioNTech COVID-19 vaccines have been distributed globally, underscoring the scale of the platform's deployment since the pandemic's onset.
Vaccine Technology and Authorization Framework
The Pfizer-BioNTech COVID-19 (搜索) vaccines are based on BioNTech's proprietary mRNA technology and were co-developed by both companies. BioNTech serves as the Marketing Authorization Holder for the vaccine and its adapted versions in the United States, the EU, the United Kingdom, and other countries, and holds emergency use authorizations or equivalents in additional jurisdictions.
The vaccine continues to demonstrate a favorable safety and efficacy profile. As with all mRNA COVID-19 (搜索) vaccines, myocarditis and pericarditis have occurred in some recipients, most commonly in males 12 through 24 years of age, with symptoms typically beginning within a week following vaccination. Common side effects include injection site reactions, tiredness, headache, muscle pain, chills, joint pain, and fever. Individuals with weakened immune systems may have a reduced immune response to the vaccine.